Cardiovascular effects of the linalool-rich essential oil of *Aniba rosaeodora* (here named as EOAR) in normotensive rats were investigated. In anesthetized rats, intravenous (i.v.) injection of EOAR induced dose-dependent biphasic hypotension and bradycardia. Emphasis was given to the first phase (phase 1) of the cardiovascular effects, which is rapid (onset time of 1–3 s) and not observed in animals submitted to bilateral vagotomy or selective blockade of neural conduction of vagal C-fibre afferents by perineural treatment with capsaicin. Phase 1 was also absent when EOAR was directly injected into the left ventricle injection, but it was unaltered by i.v. pretreatment with capsaizpine, ondansetron or HC030031. In conscious rats, EOAR induced rapid and monophasic hypotensive and bradycardiac (phase 1) effects that were abolished by i.v. methylatropine. In endothelium-intact aortic rings, EOAR fully relaxed phenylephrine-induced contractions in a concentration-dependent manner. The present findings reveal that phase 1 of the bradycardiac and depressor responses induced by EOAR has a vago-vagal reflex origin resulting from the vagal pulmonary afferents stimulation. Such phenomenon appears not to involve the recruitment of C-fibre afferents expressing 5HT3 receptors or the two chemosensory ion channels TRPV1 and TRPA1. Phase 2 hypotensive response appears resulting from a direct vasodilatory action. Copyright © 2013 John Wiley & Sons, Ltd.

**Keywords:** *Aniba rosaeodora* Ducke; essential oil; linalool; sensory C-fibres; perineural capsaicin pretreatment; vago-vagal reflex; vascular smooth muscle.
Plant material, essential oil composition and GC chiral analyses. Trunk wood from *A. roseaedora* was collected on September 2007 near the Jatapu River, municipality of Novo Aíró, State of Amazonas, Brazil. The plant was identified by comparison with an authentic voucher (MG 17.710) of *A. roseaedora*, deposited in the herbarium of Emílio Goeldi Museum, city of Belém, State of Pará, Brazil. EOAR was obtained from dried trunk wood by hydrodistillation in Clevenger-type apparatus (3 h), as previously described (Sampaio et al., 2012). The oil was dried over anhydrous sodium sulfate, and its percentage content was calculated on the basis of the plant dry weight. EOAR was also analyzed in a gas chromatography (GC) chiral column for the quantification of the enantiomers (-)-LIN and (+)-LIN. Individual components were identified by comparison of both mass spectrum and their retention time with those existing in the data system libraries and cited in the literature.

Solutions and drugs. For *in vivo* experiments, EOAR was dissolved in Tween 80 (2%), brought to the chosen volume with sterile isotonic saline under sonication. EOAR and capsaicin were injected manually as a bolus in a volume of 0.1 mL, followed by a 0.2 mL flush with physiological saline. Capsaicin was used for the peripheral treatment of the vugus at a concentration of 250 μg/mL and prepared in 1% Tween 80, 1% ethanol and 98% saline. For i.v. injection, a solution of capsaicin at a desired concentration was prepared daily by dilution with saline on the basis of an animal’s body weight. Methylatropine bromide, HC030031 and ondansetron were dissolved in saline just before use and administered in a volume of 1 mL/kg body weight. Capsazepine was first diluted in dimethyl sulphoxide to 0.1 mol/L (~37 mg/mL) and further diluted with saline containing 10% Tween 80 and 10% ethanol to a final concentration of 1 mg/mL. For *in vitro* experiments, EOAR was first dissolved in Tween 80 (0.5%), made up with the perfusion medium and sonicated just before use whereas acetylcholine was first dissolved in distilled water and was brought to volume with the perfusion medium. The perfusion medium used was fresh Krebs–Henseleit solution (KHS) (pH 7.4) of the following composition (in mM): NaCl 118; KCl 4.7; NaHCO3 25; CaCl2·2H2O 2.5; KH2PO4 1.2; MgSO4·7H2O 1.2; glucose 11 and EDTA 0.01. Drugs were purchased from Sigma (St Louis, USA) and Tocris (Ballwin, USA).

Animals. Male Wistar rats (280–320 g) were kept under standard conditions (temperature at 22 ± 2 °C; 12 h light/12 h dark cycle and food and water ad libitum). All animals were cared for in compliance with the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH Publication 85-23, revised 1996). Prior approval from local animal ethics committee (number 11043896-5) was obtained.

In vivo experiments. Catheterization procedure. Rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.), and catheters (PE-10 fused PE-50) were implanted in the abdominal aorta (for blood pressure recording) and in the inferior vena cava (for drug administration) through the left femoral artery and vein, respectively, as previously described (de Siqueira et al., 2006a). In some animals (*n* = 4), a catheter was inserted on the day of experiment into the right carotid artery and advanced retrogradely until its tip was positioned in the left ventricle. Its position was confirmed by measurement of left ventricular blood pressure and postmortem examination. Postoperatively, rats received an intramuscular injection of penicillin (24,000 IU). They were housed individually in plastic cages and allowed to recover for 24 h before any circulatory experiments.

Recording of mean arterial pressure and HR. At the time of experiment, rats were again anesthetized with sodium pentobarbital (50 mg/kg, i.p.). A short tracheal cannula was inserted via a tracheotomy, through which rats breathed spontaneously in the supine position. Baseline mean arterial pressure (MAP) and HR values were recorded on a Gilson model 5/6H (medical Electronics Inc., Middletown, WI, USA), as previously described (de Siqueira et al., 2006b, 2010).

Experimental design and protocols. In order to explore the cardiovascular responses to EOAR, the following protocol was used. Before each experiment, a period of 15–20 min was allowed to obtain a stable MAP and HR tracing. Injection response times were measured from the end of an injection to the onset of bradycardia. Injections were separated by 10 min intervals in order to avoid tachyphylaxis. Doses of agonists and antagonists were chosen according to those recommended in the literature. The following series of experiments, except series 8 (conscious rats), were performed in anesthetized rats.

In a first series of experiments which was carried out to establish a dose–effect relationship, each animal received a series of increasing bolus doses of EOAR (1, 5, 10 and 20 mg/kg, i.v.), and time course of the changes in MAP and HR was recorded (Series 1, *n* = 7). In five different groups of rats, maximal changes in MAP and HR elicited by i.v. injection of EOAR (20 mg/kg) were determined before and after a cervical bilateral vagotomy (Series 2, *n* = 6); before and after bilateral perineural treatment (PNT) with capsaicin (250 μg/mL) (de Siqueira et al., 2006b, 2010) of both cervical vagi (Series 3, *n* = 4); before and after i.v. pretreatment with competitive TRPV1 receptor antagonist, capsazepine (1 mg/kg) (Malinowska et al., 2001) (Series 4, *n* = 5); before and after i.v. pretreatment with the TRPA1 antagonist, HC030031 (8 mg/kg) (Lin et al., 2010) (Series 5, *n* = 4) and before and after the pretreatment with the 5-HT3 receptor antagonist, ondansetron (30 μg/kg) (Bagchi and Deshpande, 2001) (Series 6, *n* = 5). To determine the location of the afferent C-fibre endings involved in the cardiovascular responses, EOAR (20 mg/kg) was injected into the left ventricle bypassing therefore the pulmonary circulation and presumably do not have immediate access to the pulmonary C-fibres (Series 7, *n* = 4).

The last series of experiments (Series 8) was performed in conscious rats in order to assess the role of cholinergic mechanism in the mediation of EOAR-induced cardiovascular changes. Therefore, maximal changes in MAP and HR elicited by EOAR (10 and 20 mg/kg, i.v.) were determined in conscious rats that had been pretreated intravenously 10 min earlier with vehicle (1 mL/kg, (2013) Phytother. Res. (2013)
n = 7), or the peripheral muscarinic receptor antagonist methylatropine (1 mg/kg, n = 6) (de Siqueira et al., 2006a).

In vitro experiments. Rats were sacrificed and thoracic aortae were removed and cut into rings which were mounted in 5-mL organ baths containing gassed (5% CO2 in O2) KHS, at 37°C (pH7.4). Passive tension was 1 g, and contractions were recorded using an isometric force transducer (Grass Model FTO3, Quincy, MA, USA) connected to a PC-based Dataq acquisition system (PM-1000, CWE Inc., Akron, OH, USA). The vasorelaxant activity was studied according by constructing concentration–effect curves in response to cumulative addition of EOAR (0.15–771.25 µg/mL). Data were expressed as a percentage of the contraction induced by phenylephrine (PHE, 0.1 M).

Statistical analysis. All results are expressed as the mean ± SEM. Maximal changes in MAP and HR were expressed as a percentage of baseline values. IC50 value was calculated by interpolation from semi-logarithmic plots. Significance of results (p < 0.05) was assessed by paired Student’s t-test, Mann–Whitney U-test and one- or two-way analysis of variance (ANOVA), followed by Dunnett’s or Holm–Sidak’s multiple comparison tests when appropriate.

RESULTS

Rosewood oil showed a yield of 1.5% with a colourless to pale yellow liquid with a woody-floral fragrance. Its analysis by GC and GC-mass spectrometry showed the following composition: LINAL (87.7%, in a racemic mixture of 50.62% (-)-LINC and 49.38% (+)-LINC in a GC chiral column analysis), x-terpineol (3.1%), geraniol (1.2%), trans-LINC oxide (0.8%), cis-LINC oxide (0.7%) and minor sesquiterpenes (4.7%). In anesthetized rats, baseline MAP and HR before injection of each dose of EOAR remained essentially invariant (p > 0.05). Therefore, mean values of MAP and HR in this group of animals before any pretreatment were 109.3 ± 2.1 mmHg and 367 ± 9 beats/min, respectively (pooled data from 24 rats).

In vivo experiments

Injections of EOAR (1–20 mg/kg, i.v.) but not its vehicle elicited dose-dependent (Fig. 1, p < 0.001) hypotensive and bradycardiac effects that became significant (Fig. 1, p < 0.05) at 1 mg/kg. At 10 and 20 mg/kg of EOAR, the hypotensive (Figs. 1A and 2A) and bradycardiac (Fig. 1B and 2B) responses to EOAR were biphasic. As shown in Fig. 2 (panels A and B), the first rapid component of EOAR-induced bradycardia and hypotension (phase 1) occurred at 1–2 and 2–3 s after injection, respectively, while the second and more lasting component of EOAR-induced bradycardia and hypotension (phase 2) picked at 4–7 and 6–11 s after injection, respectively. Phase 2 hypotensive response to 10 and 20 mg/kg EOAR remained statistically significant (p < 0.05) at 1 (−37.37 ± 4.65 and −59.1 ± 3.34%, respectively), 3 (−31.23 ± 6.17 and −49.04 ± 9.31%, respectively) and 5 (−16.19 ± 4.73 and −27.97 ± 10.74%, respectively) min after the administration. Likewise, phase 2 bradycardic response to 10 and 20 mg/kg EOAR also remained statistically significant (p < 0.05) at 1 (−16.55 ± 3.63 and −31.36 ± 1.01%, respectively), 3 (−16.02 ± 3.11 and −30.54 ± 4.06%, respectively) and 5 (−12.79 ± 2.96 and −30.78 ± 8.38%, respectively) min after the administration. The profile of the cardiovascular responses induced by EOAR was comparable to the triphasic changes in MAP (effects a, b and c; Fig. 2E) and biphasic bradycardia (effects f and s; Fig. 2F) induced by capsaicin (10 µg/kg, i.v.).

When injected directly into the left ventricle, EOAR (20 mg/kg) did not evoke the rapid hypotension (Fig. 2C) and bradycardia (Fig. 2D) responses (phase 1), but induced a delayed and significant (p < 0.01) systemic hypotension (−58.41 ± 5.05%, baseline MAP = 105.3 ± 8.7 mmHg) (Fig. 2C) and bradycardia (−24.0 ± 3.0%, baseline HR = 375 ± 8 beats/min) (Fig. 2D) that occurred with a latency similar (15.80 ± 0.53 and 13.08 ± 0.77 s, respectively) as that observed for the hypotension and bradycardia (phase 2) elicited by i.v. EOAR (~ 6–11 and ~4–7 s, respectively).

Phase 1 of hypotensive and bradycardiac responses to EOAR was abolished (p < 0.001) by either bivagotomy or PNT with capsaicin while it was unaltered by capsazepine, ondansetron and HC030031 pretreatments (Fig. 3, panels A and B). By contrast, phase 2 hypotensive and bradycardiac responses to EOAR (Fig. 3, panels C and D, respectively) and 5 (−16.19 ± 4.73 and - 27.97 ± 10.74%, respectively) min after the administration. Likewise, phase 2 bradycardic response to 10 and 20 mg/kg EOAR also remained statistically significant (p < 0.05) at 1 (−16.55 ± 3.63 and −31.36 ± 1.01%, respectively), 3 (−16.02 ± 3.11 and −30.54 ± 4.06%, respectively) and 5 (−12.79 ± 2.96 and −30.78 ± 8.38%, respectively) min after the administration. The profile of the cardiovascular responses induced by EOAR was comparable to the triphasic changes in MAP (effects a, b and c; Fig. 2E) and biphasic bradycardia (effects f and s; Fig. 2F) induced by capsaicin (10 µg/kg, i.v.).

When injected directly into the left ventricle, EOAR (20 mg/kg) did not evoke the rapid hypotension (Fig. 2C) and bradycardia (Fig. 2D) responses (phase 1), but induced a delayed and significant (p < 0.01) systemic hypotension (−58.41 ± 5.05%, baseline MAP = 105.3 ± 8.7 mmHg) (Fig. 2C) and bradycardia (−24.0 ± 3.0%, baseline HR = 375 ± 8 beats/min) (Fig. 2D) that occurred with a latency similar (15.80 ± 0.53 and 13.08 ± 0.77 s, respectively) as that observed for the hypotension and bradycardia (phase 2) elicited by i.v. EOAR (~ 6–11 and ~4–7 s, respectively).

Phase 1 of hypotensive and bradycardiac responses to EOAR was abolished (p < 0.001) by either bivagotomy or PNT with capsaicin while it was unaltered by capsazepine, ondansetron and HC030031 pretreatments (Fig. 3, panels A and B). By contrast, phase 2 hypotensive and bradycardiac responses to EOAR (Fig. 3, panels C and D, respectively) and 5 (−16.19 ± 4.73 and - 27.97 ± 10.74%, respectively) min after the administration. Likewise, phase 2 bradycardic response to 10 and 20 mg/kg EOAR also remained statistically significant (p < 0.05) at 1 (−16.55 ± 3.63 and −31.36 ± 1.01%, respectively), 3 (−16.02 ± 3.11 and −30.54 ± 4.06%, respectively) and 5 (−12.79 ± 2.96 and −30.78 ± 8.38%, respectively) min after the administration. The profile of the cardiovascular responses induced by EOAR was comparable to the triphasic changes in MAP (effects a, b and c; Fig. 2E) and biphasic bradycardia (effects f and s; Fig. 2F) induced by capsaicin (10 µg/kg, i.v.).

When injected directly into the left ventricle, EOAR (20 mg/kg) did not evoke the rapid hypotension (Fig. 2C) and bradycardia (Fig. 2D) responses (phase 1), but induced a delayed and significant (p < 0.01) systemic hypotension (−58.41 ± 5.05%, baseline MAP = 105.3 ± 8.7 mmHg) (Fig. 2C) and bradycardia (−24.0 ± 3.0%, baseline HR = 375 ± 8 beats/min) (Fig. 2D) that occurred with a latency similar (15.80 ± 0.53 and 13.08 ± 0.77 s, respectively) as that observed for the hypotension and bradycardia (phase 2) elicited by i.v. EOAR (~ 6–11 and ~4–7 s, respectively).

Phase 1 of hypotensive and bradycardiac responses to EOAR was abolished (p < 0.001) by either bivagotomy or PNT with capsaicin while it was unaltered by capsazepine, ondansetron and HC030031 pretreatments (Fig. 3, panels A and B). By contrast, phase 2 hypotensive and bradycardiac responses to EOAR (Fig. 3, panels C and D,
respectively) remained unchanged by all pretreatments. In conscious rats, EOAR (10 and 20 mg/kg, i.v.) evoked significant (Fig. 4, \(p < 0.001\)), rapid and monophasic decreases in MAP and HR (phase 1, latency \(\sim 1.7-3.2\) s) which was abolished by methylatropine pretreatment (Fig. 4).

As previously reported (de Siqueira et al., 2006a, 2006b; Lahlou et al., 2007), baseline MAP and HR values remained significantly unchanged following bolus i.v. injection of the same volume (100 L) of the EOAR’s vehicle in conscious rats (\(-0.61 \pm 1.05\) and

Figure 2. Representative recordings showing changes in mean arterial pressure (MAP) and heart rate (HR) induced by intravenous injection of the essential oil of *Aniba rosaeodora* (EOAR, 20 mg/kg) (panels A and B, respectively) or capsaicin (10 \(\mu\)g/kg) (panels E and F, respectively) in anesthetized rats without any pretreatment. Panels C and D correspond to representative recordings showing changes in MAP and HR evoked by EOAR (20 mg/kg) injected into the left ventricle. Arrows indicate the time of injection. a, b, c: typical triphasic changes in blood pressure following capsaicin injection; f (fast) and s (slow): biphasic bradycardia following capsaicin injection. Panels E and F match the ones that were previously reported (de Siqueira et al., 2010).

Figure 3. Phase 1 decreases in mean arterial pressure (\(\Delta\)MAP) and heart rate (\(\Delta\)HR) (panels A and B, respectively) and phase 2 hypotensive and bradycardiac effects (panels C and D, respectively) elicited by intravenous (i.v.) administration of the essential oil of *Aniba rosaeodora* (EOAR, 20 mg/kg) in five groups of anesthetized normotensive rats: (1) before and after bivagotomy (Biv) at cervical level (\(n = 6\)), (2) before and after perineural treatment (PNT) of both cervical vagi with capsaicin (250 \(\mu\)g/mL, \(n = 5\)), (3) before and after i.v. pretreatment with capsaizepine (Capz; 1 mg/kg, \(n = 4\)), (4) before and after i.v. pretreatment with ondansetron (Ond; 30 \(\mu\)g/kg, \(n = 5\)) and (5) before and after i.v. pretreatment with HC0300031 (HC; 8 mg/kg, \(n = 4\)). Data are mean ± SEM and expressed as percentage of baseline. *\(p < 0.01\) and \#\(p < 0.05\) by paired Student’s t-test vs. the baseline values and the corresponding responses before any pretreatment, respectively.

In vitro experiments

In aortic preparations with intact endothelium, EOAR (0.15–771.25 μg/mL) relaxed the PHE-induced contractions in a concentration-dependent manner (Fig. 5; \( p < 0.001 \)) with an IC50 (geometric mean [95% confidence interval]) value of 95.08 [36.32–153.8] μg/mL. The first significant effect was observed at 46 μg/mL EOAR (Fig. 5; \( p < 0.01 \)). EOAR-induced vasorelaxant effects were reversible after wash and remained unaffected by the endothelium removal (Fig. 5, IC50 = 72.35 [43.13–101.6] μg/mL). Vehicle had no effect on PHE-induced contractions in either endothelium-containing (Fig. 5) or denuded aortic preparations (data not shown).

DISCUSSION

In this study, i.v. administration of EOAR (at 10 and 20 mg/kg) induced two periods of hypotension and bradycardia in anesthetized rats. Initially, a rapid bradycardia (onset time of 1–2 s) occurred coincidentally (onset time of 2–3 s) with an arterial hypotension (phase 1), and then a delayed and more lasting decrease in blood pressure associated with a second bradycardia (phase 2). Phase 1 responses occurred as rapidly as the vago-vagal reflex elicited by i.v. capsaicin (Donnerer and Lembeck, 1982; Yang et al., 1993) or serotonin (Owen et al., 2005). Therefore, we investigated the possibility that EOAR could induce a capsaicin- or serotonin-like bradycardiac and depressor reflex.

This study focused on phase 1 hypotensive and bradycardiac responses to EOAR. This phase was abolished in bivagotomized, anesthetized rats and by pretreatment with methylatropine in conscious rats. This indicates that this phase is mediated by a vagal reflex and an efferent cholinergic mechanism. The finding that PNT with capsazepine (Bevan et al., 1992) and an efferent reflex (Jancsó and Such, 1983) also prevented the phase 1 responses indicates that EOAR stimulates vagal sensory C-fibres to elicit vago-vagal reflex decreases in HR and blood pressure. It seems unlikely that EOAR activates vagal sensory C-fibres indirectly via its metabolites because of the too short latency of the EOAR-induced reflex response. EOAR-induced initial bradycardia and hypotensive effects (phase 1) seem to result from stimulation of pulmonary C-fibre afferents as it was absent after left ventricle injection. It is known that activation of these afferents by various chemical agents induces the transient systemic hypotension that accompanies the reflex bradycardia (Coleridge and Coleridge, 1984).

An attempt has been made to assess the receptor specificity of the EOAR-induced bradycardiac and depressor reflex. Our results suggest that neither vanilloid TRPV1 nor 5-HT3 receptors are involved in the mediation of EOAR-induced phase 1 vagus reflex, as it remained unchanged by capsazepine (Bevan et al., 1992) and ondansetron, respectively. Recently, it was reported that LIN stimulates TRPA1 receptors in dissociated dorsal root ganglia (Riera et al., 2009), and stimulation of TRPA1 receptors with i.v. cinnamaldehyde elicited immediate
and short hypotensive and bradycardiac effects (Bezold–Jarisch-like reflex) in the anesthetized mouse (Pozsgai et al., 2010). However, the present in vivo study showed that TRPA1 antagonist HC030031 failed to alter the vagus reflex evoked by EOAR which may suggest that this reflex is independent of the direct action of EOAC on TRPA1 receptors. It is noteworthy that the importance of this novel superfamily of receptors, their actual location and their pathophysiological relevance in the cardiovascular regulation are still limited. The second hypotensive response (phase 2) to i.v. EOAR seems resulting from its direct vasodilatory effect on the peripheral smooth muscle because (i) EOAR relaxed PHE-induced contractions in endothelium-intact aortic rings, (ii) a hypotensive response was also observed after left ventricle injection of EOAR and was not abolished by either bilateral vagotomy or PNT with capsaicin and finally (iii) EOAR-induced phase 2 hypotension was more potent on diastolic arterial blood pressure (Fig. 2C) suggesting that it is mainly due to decreased peripheral vascular resistance.

The EOAR sample used herein contains LIN as the major constituent (87% of the total oil). Since its inhalation in volunteers decreased HR and increased vagal nerve activity (Kuroda et al., 2005), it seems highly probable that LIN is the active principal that mediates the cardiovascular responses to EOAR. Further experiments are needed to corroborate this hypothesis and also to assess whether a pure enantiomer (e.g. (-)-LIN) could display a greater efficacy in inducing vagus reflex than the racemic mixture (±)-LIN. However, putative partial involvement of other minor constituents in the medication of EOAR-induced vago-vagal reflex cannot be excluded. Furthermore, both in vitro and in vivo effects of the EOAR were reversible excluding therefore the possibility that they might have related to a putative toxic effects of the EOAR. In fact, LIN could be classified in the group of slightly toxic substances on the basis of classification of chemical substance because its LD50 value of oral acute toxicity in rats was found greater than 2500 mg/kg (Jenner et al., 1964; Letzizia et al., 2003). The present study is of pharmacological relevance. It contributes to the little systematic studies with particular reference to hypotensive activity of A. rosaeodora. Further studies are needed to be conducted in hypertensive rats which could indicate potential application of this plant to treat hypertension in humans.

In conclusion, EOAR induces a vago-vagal bradycardiac and depressor reflex (phase 1) in anesthetized rat that appears initiated in pulmonary rather than cardiac vagal afferent fibres. The transduction mechanism of the EOAR excitation of C-fibre endings is not fully understood and seems not to involve the activation of either vallindol TRPV1, TRPA1 or 5-HT3 receptors located on vagal sensory nerves. The second hypotensive response (phase 2) to i.v. EOAR seems to result from a direct and endothelium-independent vasodilatory effect of EOAR on the peripheral vascular smooth muscle.

Acknowledgements
This research was supported by fellowships from the ‘Coordenação de Aperfeiçoamento de Pessoal de Nível Superior’ (CAPES) to KMS Rodrigues and MTB da Silva, Ph.D. students and to RJB de Siqueira (postdoctoral fellowship).

Conflict of Interest
The authors declare no conflict of interest.

REFERENCES


Bagchi S, Deshpande SB. 1999. Indian red scorpion (Buthus tamulus) venom-induced augmentation of cardiac reflexes is mediated through the involvement of peripheral 5-HT3 and central 5-HT1A receptor subtypes. Toxicol 37: 1697–1709.


